Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases

Abstract

Autologous hematopoietic stem cell transplantation (AHSCT) has been proposed as a rescue treatment in multiple sclerosis (MS) patients not responding to first- or second-line therapies. To date, most of the treated cases had a secondary progressive disease course. However, patients with high inflammatory activity, but no secondary progression of the disease, could be candidates to take greater advantage of AHSCT. In this paper, we report two cases with very active, relapsing-remitting (RR) MS, who underwent AHSCT, and obtained a dramatic resolution to disease activity. Multiple Sclerosis 2007; 13: 676-678. http://msj.sagepub.com

Keywords

autologous stem cell transplantation multiple sclerosis

Get full access to this article

View all access options for this article.

References

Blanco Y. , Saiz A. , Carreras E. , Graus F. Autologous haematopoietic-stem-cell transplantation for multiple sclerosis . Lancet Neurol 2005; 4: 54-63.

Fassas A. , Kimiskidis VK Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience. J Neurol Sci 2004; 223: 53-58.

Mancardi GL , Saccardi R. , Filippi M. , Gualandi F. , Murialdo A. , Inglese M. et al. and the Italian GITMO-NEURO Intergroup on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. Autologous hematopoietic stem cell transplantation suppresses Gdenhanced MRI activity in MS. Neurology 2001; 57: 62-68.

Muraro PA , Douek DC , Packer A. , Chung K. , Guenaga FJ , Cassiani-Ingoni R. et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 805-16.

Saccardi R. , Mancardi GL , Solari A. , Bosi A. , Bruzzi P. , Di Bartolomeo P. et al. for the Italian GITMO-Neuro Intergroup. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005; 105: 2601-607.

Burt RK , Cohen BA , Lobeck L. , Traynor AE , Bredeson C. Autologous hematopoietic stem cell transplantation in multiple sclerosis: importance of disease stage on outcome. Neurology 2003; 5: A150.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.

Comi G. , Kappos L. , Clanet M. , Ebers G. , Fassas A. , Fazekas F. et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation . J Neurol 2000; 247: 376-82.

Saiz A. , Carreras E. , Berenguer J. , Yague J. , Martinez C. , Marin P. et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 2001; 56: 1084-89.